Page 1158 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 82 Immune Reconstitution Therapy for Immunodeficiency 1123

10000

8000 T lymph B lymph NK lymph
Lymphocytes/µL 6000

4000

4000

γc def JAK3 def IL7R def RAG def Art. def ADA def Unknown Normal
N=15 N=15 N=4 N=6 N=7 N=4 N=13 range

10000

8000
Lymphocytes/µL 6000

4000

4000

γc def JAK3 def IL7R def RAG def Art. def ADA def Unknown Normal
N=11 N=11 N=4 N=3 N=3 N=4 N=6 range
+
+
FIG 82.4 Mean (±SE) numbers of CD3 T cells, CD19 B cells, and CD16 natural killer cells before
+
transplantation (A) and at the most recent evaluation after transplantation (B) performed at the
University of Brescia, Italy, according to the type of severe combined immunodeficiency (SCID).
300 Pre-HSCT Post-HSCT
TRECs (per 10 3 lymphocytes) 200
250

150

100

A 50 γc def JAK3 def IL7R def RAG def Art. def ADA def Unknown Normal
range
Proliferative response to PHA (cpm x 10 -3 ) 200
300
250

150

100

range
B 50 γc def JAK3 def IL7R def RAG def Art. def ADA def Unknown Normal
FIG 82.5 Number of T-cell receptor excision circles (TRECs) (A) and in vitro proliferative response
to phytohemagglutinin (PHA) (B) before transplantation and at the last follow-up after transplantation
in a series of 42 infants with severe combined immunodeficiency (SCID) treated at the University
of Brescia, Italy, according to the type of SCID.